Get our Free Patent Expiration Newsletter

Serving hundreds of leading biopharmaceutical companies globally:

Argus Health
Farmers Insurance
Johnson and Johnson
Merck
Baxter
McKinsey

Generated: September 23, 2019

DrugPatentWatch Database Preview

Patent: 6,632,433

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Summary for Patent: 6,632,433
Title: Method for treating cervical dystonia with botulinum toxin type B
Abstract:A method and composition for treating a patient suffering from a disease, disorder or condition and associated pain include the administration to the patient of a therapeutically effective amount of a neurotoxin selected from a group consisting of Botulinum toxin types A, B, C, D, E, F and G.
Inventor(s): Aoki; K. Roger (Laguna Hill, CA), Grayston; Michael W. (Irvine, CA), Carlson; Steven R. (Laguna Niguel, CA), Leon; Judith M. (Laguna Niguel, CA)
Assignee: Allergan, Inc. (Irvine, CA)
Application Number:09/884,830
Patent Claims:see list of patent claims

Details for Patent 6,632,433

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Elan Pharm MYOBLOC botulinum toxin type b VIAL 103846 001 2000-12-08 ➤ Sign Up Allergan, Inc. (Irvine, CA) 2013-12-28 RX company
Genzyme CAMPATH alemtuzumab VIAL; INTRAVENOUS 103948 001 2001-05-07 ➤ Sign Up Allergan, Inc. (Irvine, CA) 2013-12-28 RX Orphan company
Genzyme CAMPATH alemtuzumab VIAL; INTRAVENOUS 103948 002 2001-05-07 ➤ Sign Up Allergan, Inc. (Irvine, CA) 2013-12-28 RX Orphan company
Genzyme LEMTRADA alemtuzumab INJECTABLE;INJECTION 103948 003 2001-05-07 ➤ Sign Up Allergan, Inc. (Irvine, CA) 2013-12-28 RX Orphan company
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Citi
Johnson and Johnson
Moodys
Boehringer Ingelheim
UBS
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.